During minimally invasive interventional procedures, a series of biological reactions occur rapidly once the device surface comes into contact with blood:
1. Protein adsorption: Plasma proteins begin adhering to the device surface within seconds
2. Platelet activation: Adsorbed proteins trigger platelet aggregation and activation
3. Thrombus formation: Activated platelets and coagulation factors jointly form a thrombus
4. Inflammatory response: The immune system recognizes the foreign body and initiates an inflammatory cascade
Phosphorylcholine coatings systematically reduce the risk of thrombus formation and inflammatory responses by constructing a biomimetic interface on the device surface that inhibits protein adsorption and platelet activation at the source.
· Cardiovascular devices: Stents, catheters, guidewires
· Interventional devices: Balloon catheters, stone retrieval baskets, vena cava filters
· Implantable devices: Artificial joints, cardiac valve accessories
· Extracorporeal circulation devices: Oxygenators, dialysis tubing
· Drug-free anticoagulation mechanism with higher safety
· Excellent anti-protein adsorption and anti-cell adhesion properties
· Nanoscale ultra-thin coating that does not affect device structure
· Covalent bonding for high coating integrity
· Long-lasting and durable, independent of drug release
A top-tier manufacturer needs deep technical expertise:
· Polymer synthesis capability: In-house ability to synthesize MPC polymers
· Coating formulation development: Customized formulations for different substrates and applications
· Curing processes: In-depth mastery of UV-curing or thermal-curing processes
· Characterization and analysis: Comprehensive coating characterization and performance evaluation capabilities
The ability to transition from laboratory to mass production is a key differentiator for top-tier manufacturers:
· Quality consistency control in scaled production
· Flexible multi-product manufacturing capabilities
· Reliable supply chain assurance
· Efficient delivery capabilities
· ISO 13485 medical device quality management system certification
· Class 10,000 cleanroom production
· Complete process control and quality inspection systems
· Batch traceability and data integrity management
· Familiarity with regulatory requirements in target markets (NMPA, FDA, CE)
· Technical documentation support for registration filings
· Proven experience helping clients obtain registration certificates
· Full-process technical support from concept design to mass production
· Rapid prototyping and iteration capabilities
· Professional technical training and knowledge transfer
Cardiac stents:
· Reduces the risk of thrombus formation after stent implantation
· Inhibits intimal hyperplasia and restenosis
· Drug-free coating avoids drug-related side effects
Catheters:
· Reduces the risk of catheter-related thrombosis (CRT)
· Minimizes lumen narrowing caused by surface protein deposition
· Improves patency of long-term indwelling catheters
Balloon catheters:
· Reduces vascular wall injury response during balloon dilation
· Lowers the incidence of post-procedure thrombotic events
Stone retrieval baskets:
· Reduces tissue fragment adhesion
· Improves surgical efficiency
Long-term implants:
· The long-lasting anti-adhesion properties of phosphorylcholine coatings make them particularly suitable for long-term implant applications
· Reduces foreign body response and fibrous encapsulation
· Extends implant service life
· Extracorporeal circulation tubing: Reduces activation of blood-contacting surfaces
· Dialysis devices: Enhances biocompatibility
· Implantable sensors: Reduces the impact of tissue reactions on sensing accuracy
Technical capability: Whether the partner possesses in-house MPC polymer synthesis and coating development capabilities
Industry experience: Successful cases and industry reputation in medical device coatings
Quality system: ISO 13485 certification, cleanroom classification, process control capabilities
Production capacity: Ability to meet current and future production demands
Regulatory support: Capability to provide technical documentation support for registration filings
Global presence: Multi-region delivery and localized service support
Do you synthesize your own MPC polymers or source them externally?
What are your capabilities for controlling coating thickness and uniformity?
Can you provide complete biocompatibility test reports?
What is the typical lead time from prototyping to mass production?
Do you have experience helping clients obtain registration certificates?
How flexible is your coating formulation customization?
What is your strategy for ensuring batch-to-batch consistency?
· Inability to provide detailed coating characterization data
· Lack of successful cases for similar products
· Incomplete quality systems or expired certifications
· Insufficient understanding of regulatory requirements
· Inconsistent delivery times
· Slow technical support response
· Start with sample testing and small-batch validation
· Establish clear communication channels and feedback mechanisms
· Share technological advancements and market insights
· Enter into long-term supply agreements to protect both parties’ interests
As a leading manufacturer in the phosphorylcholine coating field, jMedtech offers the following core advantages:
Complete technology platform: In-house technology chain from MPC polymer synthesis to coating application
Proven jHemo PC® product: Nanoscale covalent bonding, drug-free anti-adhesion
Scaled manufacturing capability: Class 10,000 cleanrooms, ISO 13485 certification, 3 factories
Global service network: 600+ partners, with operations across Asia, Europe, and the Americas
One-stop solution: Integrated capabilities in coatings, tubing, equipment, and methodologies
Strategic integration advantage: Integration with Hydromer, U.S.-localized production, and 46 years of regulatory compliance experience
Extensive success stories: Proven collaboration experience with multiple leading companies
jMedtech jHemo PC® phosphorylcholine coating features nanoscale thickness and covalent bonding to achieve exceptional drug-free, anti-adhesion, and coagulation-reducing performance. Backed by 46 years of regulatory compliance experience and global regulatory recognition, jMedtech provides customized phosphorylcholine coating solutions for cardiovascular, interventional, and other medical devices, helping products accelerate their entry into global high-end markets.
The core difference lies in the anticoagulation mechanism and safety profile:
· Heparin coatings: Achieve anticoagulation by releasing heparin; carry risks of drug depletion and HIT; coating lifespan is limited by drug release rate
· Phosphorylcholine coatings: Inhibit protein adsorption and cell adhesion through a biomimetic interface; drug-free with no HIT risk; covalently bonded for long-lasting durability
For long-term indwelling devices and applications with extremely high safety requirements, phosphorylcholine coatings are generally the preferred choice.
Phosphorylcholine coatings bond to substrates through covalent bonds and offer excellent long-term performance:
· Independent of drug release, with no drug depletion issue
· Exceptionally high stability of the covalently bonded nanoscale thin film
· Maintains stable anti-adhesion performance throughout the validity period
· Specific durability depends on the usage environment and coating formulation
The following devices particularly benefit from phosphorylcholine coatings:
· Long-term indwelling cardiovascular catheters
· Implantable devices and components
· Interventional devices in prolonged contact with blood
· Diagnostic devices requiring reduced protein adsorption
· Devices where drug release is a concern
Phosphorylcholine coating products must meet the following certifications:
· ISO 10993 biocompatibility series testing
· ISO 13485 quality management system
· Regulatory registration requirements in target markets (NMPA, FDA, CE, etc.)
· Performance validation including particulate testing and stability testing
Lead time depends on order size and customization level:
· Standard product samples: 1–2 weeks
· Standard product batches: 2–4 weeks
· Custom formulation development: 4–8 weeks (including validation)
· Scaled mass production: Scheduled based on order volume and capacity
With 15 production lines and a monthly capacity of 1 million units, jMedtech delivers industry-leading turnaround times.
